MedTrace Logo

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

NCT03415854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Paricalcitol (Zemplar)

combination therapy

Sponsors & Collaborators

  • Barts Cancer Institute

    collaborator OTHER

  • Abramson Cancer Center at Penn Medicine

    collaborator OTHER

  • Salk Institute for Biological Studies

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • Princeton University

    collaborator OTHER

  • Imaging Endpoints

    collaborator UNKNOWN

  • Translational Genomics Research Institute

    collaborator OTHER

  • Stand Up To Cancer

    collaborator OTHER

  • Cancer Research UK

    collaborator OTHER

  • Lustgarten Foundation

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • HonorHealth Research Institute

    lead OTHER

Principal Investigators

  • Erkut Borazanci, MD · HonorHealth Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2023-12-11
Completion
2023-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415854 on ClinicalTrials.gov